thought call
continu like merck posit rel peer pipelin
 perspect continu top-lin growth fx impact strong
upsid ww keytruda sale trend expect prevail back half year
keytruda continu trend ahead street expect
uptak follow robust result immedi
investor hope anticip see strong keytruda penetr lung
market expand label pdufa septemb octob
submiss expect soon follow step eros market
help keep drive merck share maintain current
pace commerci execut remain import thesi confid
keytruda seemingli secur commerci posit lung understand
trepid lack gross margin growth expect next year
remain encourag merck commit develop pipelin
believ warrant caus concern continu see room meaning
upsid look base i/o upsid potenti absent need
accret deal support overweight weight rate pt
anim strategi remain despit spinoff peer seen recent
spinoff industri peer view merck commit ah diversif
portfolio consid value-ad long compani continu
drive revenu growth synerg expens human health busi
model updat made adjust model reflect strong
perform updat guidanc manag commentari today call
chang ep estim move
revenu increas
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight believ merck like
continu take share lung back
posit data addit
view perhap first-lin lung
market share grab us support
ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compani report barclay research estim
compani report barclay research estim
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg barclay merck co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
